---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011612"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T05:58:27.648026+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma reports FY2023 net loss of $18.0M; pipeline progress on influenza and COVID-19 programs

## Summary
- Net loss $18.0M ($1.87/share) vs $38.8M ($4.77/share) prior year which included $19.1M goodwill impairment.
- Cash at Dec 31, 2023: $26.4M, down from $37.1M; net cash used in ops $14.7M.
- FDA provided Pre-IND feedback clarifying requirements for Phase 2b trial of oral CC-42344 for influenza A.
- Expect topline data in 2024 from Phase 2a human challenge study with CC-42344 and Phase 1 study with CDI-988.
- Plan to initiate Phase 1 study of inhaled CC-42344 in 2024 as influenza treatment/prophylactic.

## SEC filing metadata
- accession: 0001493152-24-011612
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315224011612/0001493152-24-011612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315224011612/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011612
- JSON: https://secwatch.observer/filing/0001493152-24-011612.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011612.txt

## Key facts
- Earnings Releases
  Cocrystal Pharma, Inc. reported financial results for the 12 months ended December 31, 2023.
  - Period: the 12 months ended December 31, 2023
  - Result: reported results
  source text: Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315224011612/0001493152-24-011612-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.